David Lebovitz
Stock Analyst at Citigroup
(3.39)
# 934
Out of 4,964 analysts
90
Total ratings
67.69%
Success rate
9.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Lebovitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $364 → $404 | $443.64 | -8.94% | 32 | Jul 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Neutral | $82 → $78 | $58.50 | +33.33% | 4 | May 2, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $378 → $469 | $412.23 | +13.77% | 4 | Feb 27, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Buy | $70 → $74 | $30.09 | +145.93% | 2 | Nov 14, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $37 → $38 | $71.81 | -47.08% | 1 | May 9, 2024 | |
| PTCT PTC Therapeutics | Downgrades: Sell | $29 → $17 | $49.31 | -65.52% | 5 | Oct 27, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $57 → $54 | $99.20 | -45.56% | 5 | Aug 4, 2021 | |
| IONS Ionis Pharmaceuticals | Maintains: Underweight | $38 → $35 | $41.82 | -16.31% | 6 | May 6, 2021 | |
| MGNX MacroGenics | Maintains: Underweight | $16 → $17 | $1.64 | +936.59% | 11 | Apr 30, 2021 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Equal-Weight | $12 → $11 | $1.27 | +766.14% | 7 | Feb 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $194 → $199 | $190.37 | +4.53% | 11 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $510 → $480 | $6.31 | +7,506.97% | 2 | Nov 3, 2020 |
Alnylam Pharmaceuticals
Jul 11, 2025
Maintains: Buy
Price Target: $364 → $404
Current: $443.64
Upside: -8.94%
BioMarin Pharmaceutical
May 2, 2025
Maintains: Neutral
Price Target: $82 → $78
Current: $58.50
Upside: +33.33%
Madrigal Pharmaceuticals
Feb 27, 2025
Maintains: Buy
Price Target: $378 → $469
Current: $412.23
Upside: +13.77%
Crinetics Pharmaceuticals
Nov 14, 2024
Maintains: Buy
Price Target: $70 → $74
Current: $30.09
Upside: +145.93%
Mirum Pharmaceuticals
May 9, 2024
Maintains: Buy
Price Target: $37 → $38
Current: $71.81
Upside: -47.08%
PTC Therapeutics
Oct 27, 2023
Downgrades: Sell
Price Target: $29 → $17
Current: $49.31
Upside: -65.52%
Rhythm Pharmaceuticals
Aug 4, 2021
Maintains: Overweight
Price Target: $57 → $54
Current: $99.20
Upside: -45.56%
Ionis Pharmaceuticals
May 6, 2021
Maintains: Underweight
Price Target: $38 → $35
Current: $41.82
Upside: -16.31%
MacroGenics
Apr 30, 2021
Maintains: Underweight
Price Target: $16 → $17
Current: $1.64
Upside: +936.59%
Ironwood Pharmaceuticals
Feb 22, 2021
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $1.27
Upside: +766.14%
Nov 13, 2020
Maintains: Overweight
Price Target: $194 → $199
Current: $190.37
Upside: +4.53%
Nov 3, 2020
Maintains: Overweight
Price Target: $510 → $480
Current: $6.31
Upside: +7,506.97%